Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today! Enjoy a flat 15% OFF on all 2025 Global Market Reports until March 31st! Use code FY25SAVE to save big—don’t miss out!
How has the onpattro market grown over the years?
In recent years, the Onpattro market size has surged at a XX (HCAGR). It is predicted to experience an increase from $XX million in 2024 to $XX million in 2025, reflecting a compound annual growth rate (CAGR) of XX%. This growth throughout the historic phase is primarily a result of factors such as the increasing incidence of hereditary transthyretin-mediated amyloidosis, heightened recognition of rare diseases, greater investment in research and development, an elder demographic, and an escalation in healthcare spending.
What Is the forecasted market size and growth rate for the onpattro market?
In the coming years, the size of the onpattro market is projected to experience an XX (FCAGR). By 2029, it is predicted to reach $XX million, with a compound annual growth rate (CAGR) of XX%. This growth during the forecast period can be traced back to strategic collaborations and licensing, regulatory assistance, an increased occurrence of chronic diseases, growing partnerships in biopharmaceuticals, and an increased number of transthyretin amyloidosis cases. The major trends for the forecast period encompassing wider acceptance of ribonucleic acid-based therapies, increase in orphan drug authorizations, the incorporation of digital health tools, a shift towards customized medicine, and advancements in technology for drug delivery.
Get your onpattro market report here!
https://www.thebusinessresearchcompany.com/report/onpattro-global-market-report
What are the major factors driving growth in the onpattro market?
The increasing occurrences of inherited transthyretin-induced amyloidosis are predicted to spur the development of the onpattro market in the future. Inherited transthyretin-induced amyloidosis (hATTR) is an uncommon genetic condition where altered TTR proteins generate damaging accumulations, impacting nerves and the heart. The growing instances of this disorder are incited by enhanced diagnostics, genetic testing, and elevated awareness, leading to the identification of more cases. Onpattro serves as a treatment for this disorder, suppressing the transthyretin (TTR) gene to minimize the production of amyloid protein and deter organ damage. For example, in February 2024 as per Verywell Health, a health information platform based in the U.S, hereditary transthyretin-induced amyloidosis globally impacts between 5,500 to 38,500 individuals. The U.S itself records between 104 to 3,847 cases of this disorder accompanied by polyneuropathy, emphasizing significant underdiagnosis. As such, the escalating prevalence of inherited transthyretin-induced amyloidosis is stimulating the expansion of the onpattro market.
What key areas define the segmentation of the global onpattro Market?
The onpattro market covered in this report is segmented –
1) By Clinical Indication: Hereditary Transthyretin-Mediated Amyloidosis, Wild-Type Transthyretin Amyloidosis, Other Transthyretin-Related Amyloidoses
2) By Distribution Channel: Direct Sales, Pharmacies, Online Pharmacies
3) By End User: Hospitals, Specialty Clinics, Home Healthcare Providers
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20169&type=smp
What are the top market players propelling the growth of the onpattro industry?
Major companies operating in the onpattro market include Alnylam Pharmaceuticals Inc.
What are the key trends shaping the future of the onpattro market?
The prevailing pattern in the onpattro market involves an expansion of the drug’s indications through additional drug applications with the objective of maximizing its market viability and catering to a more diverse set of patient requirements. Additional drug applications commonly serve to broaden the officially recognized uses of a drug, such as targeting new medical conditions, demographics, or drug formulations, to extend its therapeutic effect and market reach. For instance, Alnylam Pharmaceuticals, a pharmaceutical firm based in the US, declared the acceptance of a Supplemental New Drug Application (sNDA) for ONPATTRO (patisiran) in February 2023. This treatment focuses on managing cardiomyopathy linked to transthyretin amyloidosis (ATTR). ONPATTRO, an RNA interference (RNAi) treatment, is engineered to specifically target the transthyretin (TTR) protein, which in patients with ATTR amyloidosis, can gather anomalously and lead to serious health conditions like cardiomyopathy. The drug was initially given approval in 2018 to treat polyneuropathy associated with inherited ATTR amyloidosis. The recent sNDA submission was based on the findings from the Phase III APOLLO-B study which showed that patisiran greatly enhanced the functional capacity and quality of life in patients suffering from cardiomyopathy compared to a placebo.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20169
What regions are dominating the onpattro market growth?
North America was the largest region in the onpattro market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the onpattro market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Browse Through More Similar Reports By The Business Research Company:
Neuroprosthetics Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/neuroprosthetics-global-market-report
Neuroscience Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/neuroscience-global-market-report
Diabetic Neuropathy Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/diabetic-neuropathy-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on: